Statistik Asas
| CIK | 1510964 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CV Sciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sciences, Inc. (Exact |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 13, 2025 |
CV Sciences, Inc. Reports Second Quarter 2025 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2025 Financial Results San Diego, CA - August 13, 2025 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quart |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 14, 2025 |
CV Sciences, Inc. Reports First Quarter 2025 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports First Quarter 2025 Financial Results San Diego, CA - May 14, 2025 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter e |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sciences, Inc. (Exac |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 27, 2025 |
Amendment No. 1 to Stock Purchase Agreement AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT (this “Amendment”) is dated as of January 15, 2025, and is made and entered into by and among CV SCIENCES, INC., a Delaware corporation (the “Purchaser”), EXTRACT LABS INC., a Colorado corporation (the “Company”), CRAIG HENDERSON, an individual (“Henderson”), and HIGHER LOVE WELLNESS COMPANY, LLC, a Colora |
|
| March 27, 2025 |
Exhibit 19.1 CV SCIENCES, INC. INSIDER TRADING POLICY This Insider Trading Policy provides the standards of CV Sciences, Inc. (the “Company”) on trading and causing the trading of the Company’s securities or securities of other publicly-traded companies while in possession of confidential information. This policy is divided into two parts: the first part prohibits trading in certain circumstances |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Science |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 27, 2025 |
Exhibit 21.1 List of Subsidiaries Domestic Entities Jurisdiction of Formation Elevated Softgels LLC Delaware Star Sky Foods, LLC Delaware Foreign Entity Jurisdiction of Formation Cultured Foods Sp. z.o.o. Poland |
|
| March 27, 2025 |
STOCK PURCHASE AGREEMENT by and among CV SCIENCES, INC. EXTRACT LABS INC., CRAIG HENDERSON AND HIGHER LOVE WELLNESS COMPANY, LLC NOVEMBER 15, 2024 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of November 15, 2024, is made and entered into by and among CV SCIENCES, INC., a Delaware corporation (the “Purchaser”), EXTRACT LABS INC., a Colorado corporation (the “ |
|
| March 27, 2025 |
CV Sciences, Inc. Reports Fiscal Year-End 2024 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2024 Financial Results San Diego, CA - March 27, 2025 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year |
|
| February 20, 2025 |
Security Agreement dated February 12, 2025 [Certain information has been excluded because it both (i) is not material and (ii) is the type the Company treats as private or confidential] SECURITY AGREEMENT SECURITY AGREEMENT, dated as of February 12, 2025 (this “Agreement”), among CV Sciences, Inc. |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 20, 2025 |
Intellectual Property Security Agreement dated February 12, 2025 [Certain information has been excluded because it both (i) is not material and (ii) is the type the Company treats as private or confidential] INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (“IP Security Agreement”) dated as of February 12, 2025, is made and entered into by and among CV Sciences, Inc. |
|
| February 20, 2025 |
Securities Purchase Agreement dated February 12, 2025 [Certain information has been excluded because it both (i) is not material and (ii) is the type the Company treats as private or confidential] SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as February 12, 2025, among CV Sciences, Inc. |
|
| February 20, 2025 |
Senior Secured Note Due August 12, 2026 [Certain information has been excluded because it both (i) is not material and (ii) is the type the Company treats as private or confidential] THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 21, 2024 |
CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs Exhibit 99.1 CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs San Diego, CA - November 21, 2024 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it has entered int |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sciences, Inc. ( |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 14, 2024 |
CV Sciences, Inc. Reports Third Quarter 2024 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter 2024 Financial Results San Diego, CA - November 14, 2024 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quart |
|
| August 13, 2024 |
Exhibit 2.5 MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among CV SCIENCES, INC. ELEVATED SOFTGELS LLC, CLAYTON J. MONTGOMERY, CHRIS FAGAN, ANDREW KESTER, AND TIMOTHY MCGREER - i - DOCPROPERTY DocID \* MERGEFORMAT 120416-00000001/7531387.2 MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS MEMBERSHIP PURCHASE AGREEMENT (this “Agreement”), dated as of May 8, 2024, is made and entered into by and among CV |
|
| August 13, 2024 |
CV Sciences, Inc. Reports Second Quarter 2024 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2024 Financial Results San Diego, CA - August 13, 2024 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarte |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sciences, Inc. (Exact |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 9, 2024 |
Security Agreement between the Company and Streeterville Capital, LLC dated July 3, 2024 Exhibit 10.3 Security Agreement This Security Agreement (this “Agreement”), dated as of July 3, 2024, is executed by CV Sciences, Inc., a Delaware corporation (“Debtor”), in favor of Streeterville Capital, LLC, a Utah limited liability company (“Secured Party”). A. Debtor has issued to Secured Party a certain Secured Promissory Note of even date herewith, as may be amended from time to time, in th |
|
| July 9, 2024 |
Note Purchase Agreement between the Company and Streeterville Capital, LLC dated July 3, 2024 Exhibit 10.1 Note Purchase Agreement This Note Purchase Agreement (this “Agreement”), dated as of July 3, 2024, is entered into by and between CV Sciences, Inc., a Delaware corporation (“Company”), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering this Agreement in reliance upon an exem |
|
| July 9, 2024 |
Secured Promissory Note issued to Streeterville Capital, LLC dated July 3, 2024 Exhibit 10.2 SECURED PROMISSORY NOTE Effective Date: July 3, 2024 U.S. $1,188,500.00 FOR VALUE RECEIVED, CV Sciences, Inc., a Delaware corporation (“Borrower”), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (“Lender”), $1,188,500.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is twelve (12) months |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 25, 2024 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of June 20, 2024 (the “Effective Date”), by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and JOSEPH DOWLING ("Executive"). Recitals A. The Company and Executive entered into that certain Executive Employment Agreement dated June 23, 2021, as modified per t |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 25, 2024 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of June 20, 2024 (the “Effective Date”), by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and JOERG GRASSER ("Executive"). Recitals A. The Company and Executive entered into that certain Executive Employment Agreement dated December 17, 2021, as modified pe |
|
| June 7, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 15, 2024 |
Exhibit 2.1 MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among CV SCIENCES, INC. ELEVATED SOFTGELS LLC, CLAYTON J. MONTGOMERY, CHRIS FAGAN, ANDREW KESTER, AND TIMOTHY MCGREER - i - DOCPROPERTY DocID \* MERGEFORMAT 120416-00000001/7531387.2 MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS MEMBERSHIP PURCHASE AGREEMENT (this “Agreement”), dated as of May 8, 2024, is made and entered into by and among CV |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sciences, Inc. (Exac |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 14, 2024 |
CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER Exhibit 99.1 CV SCIENCES, INC. ACQUIRES ELEVATED SOFTGELS A FLEXIBLE, LOW-MOQ, NUTRACEUTICAL MANUFACTURER San Diego, CA - May 13, 2024 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced that it ha |
|
| May 14, 2024 |
CV Sciences, Inc. Reports First Quarter 2024 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports First Quarter 2024 Financial Results San Diego, CA - May 14, 2024 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter en |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 29, 2024 |
Exhibit 2.4 MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among CV SCIENCES, INC. CULTURED FOODS, BARBARA McWHORTER, AND BRIAN CARL McWHORTER DECEMBER 7, 2023 - i - MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS MEMBERSHIP PURCHASE AGREEMENT (this “Agreement”), dated as of December 7, 2023, is made and entered into by and among CV SCIENCES, INC., a Delaware corporation filed with the Secretary of Sta |
|
| March 29, 2024 |
Exhibit 21.1 List of Subsidiaries Domestic Entities Jurisdiction of Formation Star Sky Foods, LLC Delaware Foreign Entity Jurisdiction of Formation Cultured Foods Sp. z.o.o. Poland |
|
| March 29, 2024 |
Exhibit 19.1 CV SCIENCES, INC. INSIDER TRADING POLICY This Insider Trading Policy provides the standards of CV Sciences, Inc. (the “Company”) on trading and causing the trading of the Company’s securities or securities of other publicly-traded companies while in possession of confidential information. This policy is divided into two parts: the first part prohibits trading in certain circumstances |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Science |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 CV SCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-54677 80-0944970 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 28, 2024 |
CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results San Diego, CA - March 28, 2024 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year a |
|
| December 12, 2023 |
Exhibit 99.1 CV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market Opening Door For European Distribution San Diego, CA – December 12, 2023 (PR NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, tod |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2023 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 C |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2023 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 14, 2023 |
CV Sciences, Inc. Reports Third Quarter 2023 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter 2023 Financial Results San Diego, CA - November 14, 2023 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quart |
|
| August 14, 2023 |
CV Sciences, Inc. Reports Second Quarter 2023 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2023 Financial Results San Diego, CA - August 14, 2023 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarte |
|
| August 14, 2023 |
Form of Stock Option Grant Notice and Form of Stock Option Agreement CV Sciences, Inc. Stock Option Grant Notice 2023 Equity Incentive Plan FOR GOOD AND VALUABLE CONSIDERATION, CV Sciences, Inc. (the “Company”), hereby grants to the Optionee named below, a stock option (the “Option”) to purchase any part or all of the specified number of shares of its Common Stock (“Option Shares”), upon the terms and subject to the conditions set forth in this Stock Option Grant N |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sci |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File |
|
| June 5, 2023 |
CV Sciences, Inc. 2023 Equity Incentive Plan CV Sciences, Inc. 2023 EQUITY INCENTIVE PLAN Plan Adopted by the Board: April 11, 2023 Plan Approved by the Shareholders: June 1, 2023 Termination Date: April 11, 2033 1. General. (a) Purposes. The purposes of the Plan are as follows: (i) To provide additional incentive for selected Employees, Directors and Consultants to further the growth, development and financial success of the Company by prov |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2023 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sc |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 15, 2023 |
CV Sciences, Inc. Reports First Quarter 2023 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports First Quarter 2023 Financial Results San Diego, CA - May 15, 2023 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter en |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive |
|
| March 30, 2023 |
Exhibit 10.45 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT (this "Amendment") is entered into as of January 5, 2023, by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and JOSEPH DOWLING ("Executive"). Recitals A. The Company and Executive entered into that certain Executive Employment Agreement dated June 22, 2021 |
|
| March 30, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Science |
|
| March 30, 2023 |
Exhibit 10.46 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT (this "Amendment") is entered into as of January 5, 2023, by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and JOERG GRASSER ("Executive"). Recitals A.The Company and Executive entered into that certain Executive Employment Agreement dated December 17, 202 |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2023 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 29, 2023 |
CV Sciences, Inc. Reports Fiscal Year-End 2022 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2022 Financial Results San Diego, CA - March 29, 2022 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year a |
|
| March 2, 2023 |
CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation Exhibit 99.3 CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation San Diego, CA - March 2, 2023 (PR NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences has received p |
|
| March 2, 2023 |
amendednoticeofsettlemen TO: ALL PERSONS WHO OWNED CANNAVEST CORP., NOW KNOWN AS CV SCIENCES, INC. (“CV SCIENCES”), COMMON STOCK AS OF APRIL 18, 2022. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. IT CONTAINS IMPORTANT INFORMATION ABOUT YOUR LEGAL RIGHTS. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT OF A SHAREHOLDER DERIVATIVE ACTION AND CLAIMS ASSERTED ON BEHALF OF CV SCIENCES (THE “ACTI |
|
| March 2, 2023 |
stipulationandagreemento Case 2:15-cv-00481-RFB-VCF Document 105-3 Filed 06/01/22 Page 2 of 51 Case 2:15-cv-00481-RFB-VCF Document 105-3 Filed 06/01/22 Page 3 of 51 Case 2:15-cv-00481-RFB-VCF Document 105-3 Filed 06/01/22 Page 4 of 51 Case 2:15-cv-00481-RFB-VCF Document 105-3 Filed 06/01/22 Page 5 of 51 Case 2:15-cv-00481-RFB-VCF Document 105-3 Filed 06/01/22 Page 6 of 51 Case 2:15-cv-00481-RFB-VC |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 14, 2022 |
CV Sciences, Inc. Reports Third Quarter 2022 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter 2022 Financial Results San Diego, CA - November 14, 2022 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quart |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 C |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 21, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File |
|
| September 27, 2022 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ALDRICH LAW FIRM, LTD. |
|
| September 27, 2022 |
NOTICE OF PROPOSED SETTLEMENT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ALDRICH LAW FIRM, LTD. |
|
| September 27, 2022 |
ORDER PRELIMINARILY APPROVING SETTLEMENT AND PROVIDING FOR NOTICE 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ALDRICH LAW FIRM, LTD. |
|
| September 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 21, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 27, 2022 |
CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation Exhibit 99.4 CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation San Diego, CA - September 27, 2022 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences has re |
|
| August 25, 2022 |
Secured Promissory Note, dated August 19, 2022 Exhibit 10.2 SECURED PROMISSORY NOTE Effective Date: August 19, 2022 U.S. $2,000,000.00 FOR VALUE RECEIVED, CV Sciences, Inc., a Delaware corporation (?Borrower?), promises to pay to Streeterville Capital, LLC, a Utah limited liability company, or its successors or assigns (?Lender?), $2,000,000.00 and any interest, fees, charges, and late fees accrued hereunder on the date that is nine (9) months |
|
| August 25, 2022 |
Security Agreement, dated August 19, 2022 Exhibit 10.3 Security Agreement This Security Agreement (this ?Agreement?), dated as of August 19, 2022, is executed by CV Sciences, Inc., a Delaware corporation (?Debtor?), in favor of Streeterville Capital, LLC, a Utah limited liability company (?Secured Party?). A. Debtor has issued to Secured Party a certain Secured Convertible Promissory Note of even date herewith, as may be amended from time |
|
| August 25, 2022 |
Note Purchase Agreement, dated August 19, 2022 Exhibit 10.1 Note Purchase Agreement This Note Purchase Agreement (this ?Agreement?), dated as of August 19, 2022, is entered into by and between CV Sciences, Inc., a Delaware corporation (?Company?), and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or assigns (?Investor?). A. Company and Investor are executing and delivering this Agreement in reliance upon an e |
|
| August 25, 2022 |
CV Sciences, Inc. Extinguishes Convertible Debt Exhibit 99.1 CV Sciences, Inc. Extinguishes Convertible Debt San Diego, CA - August 25, 2022 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, announced today that CV Sciences extinguished its entire outstanding |
|
| August 25, 2022 |
Cancellation Agreement and Mutual Release, dated August 19, 2022 Exhibit 10.4 CANCELLATION AGREEMENT AND MUTUAL GENERAL RELEASE THIS CANCELLATION AGREEMENT AND MUTUAL GENERAL RELEASE (this ?Agreement?), dated as of August 18, 2022 (the ?Effective Date?), is made by and between (i) 3i, LP (?Holder?), and (ii) CV Sciences, Inc. (the ?Company?), with reference to the following facts: A. The Company and Holder are parties to (i) that certain Securities Purchase Agr |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2022 |
CV Sciences, Inc. Reports Second Quarter 2022 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2022 Financial Results San Diego, CA - August 15, 2022 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarte |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2022 |
Exhibit 3.9 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF CV SCIENCES, INC. CV Sciences, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (?DGCL?), does hereby certify that: 1.The name of the corporation is CV Sciences, Inc. (the ?Corporation?). 1.The original Certificate of Incorporation was filed with the Secretary of State of th |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sci |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 24, 2022 |
Forbearance Agreement, dated May 18, 2022 Exhibit 10.1 FORBEARANCE AGREEMENT This Forbearance Agreement (the ?Agreement?), dated May 18, 2022, is by and between CV Sciences, Inc., a Delaware corporation (the ?Company?), and (the ?Investor?). In this Agreement, the Company and the Investor may each be referred to individually as a ?Party? and collectively as the ?Parties.? Unless otherwise defined in this Agreement, capitalized terms have |
|
| May 16, 2022 |
CV Sciences, Inc. Reports First Quarter 2022 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports First Quarter 2022 Financial Results San Diego, CA - May 16, 2022 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Financial a |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sc |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 4, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Science |
|
| April 4, 2022 |
Description of Registrant's Securities. Exhibit 4.2 DESCRIPTION OF SECURITIES The following is a summary of the material terms and provisions of the securities of CV Sciences, Inc. (?us,? ?our,? ?we? or the ?Company?) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended, and certain provisions of our certificate of incorporation (the ?Certificate of Incorporation?), and bylaws, as amended (the ?Bylaws? |
|
| April 4, 2022 |
Amendment to amended and restated Equity Incentive Plan, as amended, dated March 30, 2022. Exhibit 10.40 FIRST AMENDMENT TO CV SCIENCES, INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN Dated: March 30, 2022 WHEREAS, the Board of Directors (the ?Board?) and stockholders of CV Sciences, Inc., a Delaware corporation (the ?Company?), have adopted the Company?s Amended and Restated 2013 Equity Incentive Plan, dated as of June 3, 2014, as amended by the Board (and, in each case, as appro |
|
| April 1, 2022 |
Form of Warrant, dated March 30, 2022 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT CV SCIENCES, INC. Warrant Shares: 10,000,000 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, , or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Shareholder Approval Date (the ?Initial Exercise Date |
|
| April 1, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR For Period Ended: December 31, 2021 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this Form shall be construed to imply that the Co |
|
| April 1, 2022 |
Certificate of Designation of Preference, Rights and Limitations of Convertible Preferred Stock. Exhibit 3.1 CV SCIENCES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Joseph Dowling does hereby certify that: 1. He is the President and Secretary of CV Sciences, Inc., a Delaware corporation (the ?Corporation?). 2. The Corporation is authorized to iss |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 1, 2022 |
Form of Securities Purchase Agreement dated March 30, 2022 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 30, 2022, between CV Sciences, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set |
|
| April 1, 2022 |
Form of Placement Agent Warrant, dated March 30, 2022 Exhibit 4.2 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT CV SCIENCES, INC. Warrant Shares: THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, , or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Shareholder Approval Date (the ? |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 31, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-237772 PROSPECTUS SUPPLEMENT (To Prospectus dated April 30, 2020) 700 Shares of Preferred Stock Warrants to Purchase up to 10,000,000 Shares of Common Stock Placement Agent Warrants to Purchase up to 750,000 Shares of Common Stock (and 20,750,000 shares of Common Stock issuable upon the conversion of such Preferred Stock and exercise of such Wa |
|
| March 31, 2022 |
CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results San Diego, CA - March 31, 2022 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2021. Fiscal 2021 and Recent Financial and |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 25, 2022 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 28, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-237772 PROSPECTUS SUPPLEMENT (To Prospectus dated April 30, 2020) $1,060,000 SENIOR CONVERTIBLE NOTES DUE 2022 Shares of Common Stock Issuable Upon Conversion of the Senior Convertible Notes due 2022 CV Sciences, Inc. (the ?Company?, ?we?, ?us? or ?our?) is offering pursuant to this prospectus supplement and the accompanying base prospectus, $1 |
|
| March 28, 2022 |
Form of Second Supplemental Indenture Exhibit 4.2 CV SCIENCES, INC. TO SECOND SUPPLEMENTAL INDENTURE TO INDENTURE DATED NOVEMBER 17, 2021 Dated as of March 25, 2022 WILMINGTON SAVINGS FUND SOCIETY, FSB, as Trustee Senior Convertible Notes Due 2022 CV SCIENCES, INC. SECOND SUPPLEMENTAL INDENTURE TO INDENTURE DATED NOVEMBER, 2021 SENIOR CONVERTIBLE NOTES DUE 2022 SECOND SUPPLEMENTAL INDENTURE, dated as of March 25, 2022 (this ?Second Su |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 21, 2021 |
Employment Agreement, dated December 17, 2021, by and between the Company and Mr. Joerg Grasser. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of December 17, 2021 (the ?Effective Date?), by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and JOERG GRASSER ("Executive"). Recitals A.The Company and Executive entered into that certain Executive Employment Agreement dated December 26, 2018, as modified |
|
| December 1, 2021 |
Letter from Deloitte & Touche LLP to Securities and Exchange Commission dated November 30, 2021. Exhibit 16.1 November 30, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of CV Sciences Inc. Form 8-K dated November 30, 2021, and have the following comments: ?We agree with the statements made in the first sentence of the first paragraph, and the second through fifth paragraph of Item 4.01(a). ?We have no basis on w |
|
| December 1, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporat |
|
| November 30, 2021 |
CV Sciences, Inc. Appoints Haskell & White LLP as Auditor Exhibit 99.1 CV Sciences, Inc. Appoints Haskell & White LLP as Auditor San Diego, CA - November 30, 2021 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has appointed Haskell & White LLP ("H&W") as the Company's new independent registered public |
|
| November 30, 2021 |
Letter from Deloitte & Touche LLP to Securities and Exchange Commission dated November 30, 2021. Exhibit 16.1 Deloitte & Touche LLP 12830 El Camino Real Suite 600 San Diego, CA 92130 USA Tel:+1 619 232 6500 Fax:+1 619 237 6802 www.deloitte.com November 30, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of CV Sciences, Inc. Form 8-K dated November 30, 2021, and we agree with the statements made therein. Yours trul |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 C |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 15, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-237772 PROSPECTUS SUPPLEMENT (To Prospectus dated April 30, 2020) $1,060,000 SENIOR CONVERTIBLE NOTES DUE 2022 Shares of Common Stock Issuable Upon Conversion of the Senior Convertible Notes due 2022 CV Sciences, Inc. (the ?Company?, ?we?, ?us? or ?our?) is offering pursuant to this prospectus supplement and the accompanying base prospectus, $1 |
|
| November 15, 2021 |
Form of Supplemental Indenture Exhibit 4.2 CV SCIENCES, INC. TO [FIRST] [SECOND] [THIRD] [FOURTH] [FIFTH] SUPPLEMENTAL INDENTURE TO INDENTURE DATED [ , 2021] Dated as of [ , 2021 WILMINGTON SAVINGS FUND SOCIETY, FSB, as Trustee Senior Convertible Notes Due 2022 CV SCIENCES, INC. [FIRST] [SECOND] [THIRD] [FOURTH] [FIFTH] SUPPLEMENTAL INDENTURE TO INDENTURE DATED [], 2021 SENIOR CONVERTIBLE NOTES DUE 2022 [FIRST] [SECOND] [THIRD] |
|
| November 15, 2021 |
, 2021, between CV Sciences, Inc. and the Investor Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of November 14, 2021, is by and among CV Sciences, Inc., a Delaware corporation with offices located at 10070 Barnes Canyon Rd., San Diego, California 92121 (the ?Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and collectively, th |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 15, 2021 |
Form of Senior Convertible Note Exhibit 4.3 [FORM OF SENIOR CONVERTIBLE NOTE] THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDINGLY, THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 3(c)(iii) OF THIS NOTE. THIS NOTE HAS BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT (?OID?). PURSUANT TO TREASURY REGULATION ?1.1275-3(b)(1), JOERG GRASSER, A REPRESENTAT |
|
| November 15, 2021 |
CV Sciences, Inc. Announces Closing of Convertible Note Financing Exhibit 99.1 CV Sciences, Inc. Announces Closing of Convertible Note Financing San Diego, CA - November 15, 2021 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a securities purchase agreement with an institutional investor, prov |
|
| November 15, 2021 |
Form of Base Indenture between CV Sciences, Inc. and Wilmington Savings Fund Exhibit 4.1 CV SCIENCES, INC. INDENTURE Dated as of , 20 WILMINGTON SAVINGS FUND SOCIETY, FSB, Trustee TABLE OF CONTENTS Page ARTICLE I......... DEFINITIONS AND INCORPORATION BY REFERENCE.......................1 Section 1.1.......... Definitions........................................................................................... 1 Section 1.2.......... Other Definitions...................... |
|
| November 15, 2021 |
CV Sciences, Inc. Reports Third Quarter 2021 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter 2021 Financial Results San Diego, CA - November 15, 2021 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended September 30, 2021. Third Quarter 2021 and Recent Fi |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 24, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 13, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2021 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sci |
|
| August 12, 2021 |
CV Sciences, Inc. Reports Second Quarter 2021 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2021 Financial Results San Diego, CA - August 12, 2021 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended June 30, 2021. Second Quarter 2021 and Recent Financi |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File |
|
| July 30, 2021 |
Amendment No. 1 to Executive Employment Agreement Exhibit 10.1 AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EXECUTIVE EMPLOYMENT AGREEMENT (this "Amendment") is entered into as of June 26, 2021 (the ?Effective Date?), by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and JOERG GRASSER ("Executive"). Recitals A.The Company and Executive entered into that certain Executive Employment Agreement da |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 26, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 29, 2021 |
Employment Agreement, dated June 23, 2021, by and between the Company and Mr. Joseph Dowling Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of June 23, 2021 (the ?Effective Date?), by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and JOSEPH DOWLING ("Executive"). Recitals A.The Company and Executive entered into that certain Executive Employment Agreement dated June 14, 2018, and this Agreement |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 14, 2021 |
Amendment to the Bylaws of the Company, as amended Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE BYLAWS OF CV SCIENCES, INC., a Delaware corporation In accordance with Article IX of the bylaws of CV Sciences, Inc. (the ?Corporation?) and Article V of the certificate of the incorporation of the Corporation, by the unanimous approval of the board of directors of the Corporation, the bylaws of the Corporation are hereby amended as follows: 1.Article II |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sc |
|
| May 13, 2021 |
CV Sciences, Inc. Reports First Quarter 2021 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports First Quarter 2021 Financial Results San Diego, CA - May 13, 2021 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the ?Company?, ?CV Sciences?, ?our?, ?us? or ?we?), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2021. First Quarter 2021 and Recent Operating H |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Definitive Proxy Statement ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as p |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Definitive Proxy Statement ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as p |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Definitive Proxy Statement ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as p |
|
| March 19, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Science |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2021 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 18, 2021 |
CV Sciences, Inc. Reports Fiscal Year-End 2020 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2020 Financial Results San Diego, CA - March 18, 2021 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2020. Fiscal 2020 and Recent Operating High |
|
| December 8, 2020 |
$10,000,000 and 185,454 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-237772 PROSPECTUS SUPPLEMENT (To Prospectus dated April 21, 2020) $10,000,000 and 185,454 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to $10,000,000 of shares of our common stock, or Purchase Shares, that we may sell to Tumim Stone Capital LLC (“Tumim”), from time to time pursuant to the purchase agr |
|
| December 8, 2020 |
CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction Exhibit 99.1 CV Sciences, Inc. Announces Closing of Committed Equity Financing Transaction San Diego, CA – December 8, 2020 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a Common Stock Purchase Agreement with Tumim Stone Capita |
|
| December 8, 2020 |
Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT Dated as of DECEMBER 4, 2020 by and between CV SCIENCES, INC. and TUMIM STONE CAPITAL, LLC TABLE OF CONTENTS Article I PURCHASE AND SALE OF COMMON STOCK 1 Section 1.1 Purchase and Sale of Stock 1 Section 1.2 Commencement Date; Settlement Dates 1 Section 1.3 Reservation of Common Stock 2 Section 1.4 Current Report; Prospectus Supplement 2 Article II FIXE |
|
| December 8, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2020 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 C |
|
| November 5, 2020 |
CV Sciences, Inc. Reports Third Quarter 2020 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter 2020 Financial Results San Diego, CA - November 5, 2020 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended September 30, 2020. Third Quarter 2020 and Recent Ope |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File |
|
| August 7, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2020 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sci |
|
| August 6, 2020 |
CV Sciences, Inc. Reports Second Quarter 2020 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2020 Financial Results San Diego, CA - August 6, 2020 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended June 30, 2020. Second Quarter 2020 and Recent Operatin |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-54677 80-0944970 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 16, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-54677 (Commission Fi |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Definitive Proxy Statement ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p |
|
| May 20, 2020 |
CV SCIENCES, INC. Announces Plan to Adjourn Annual Meeting of Stockholders to June 16, 2020 Exhibit 99.1 CV SCIENCES, INC. Announces Plan to Adjourn Annual Meeting of Stockholders to June 16, 2020 SAN DIEGO, May 20, 2020 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will adjourn its 2020 Annual Meeting of Stockholders to June 16, 2020 in order to |
|
| May 20, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 000-54677 (Commission Fil |
|
| May 8, 2020 |
CV Sciences, Inc. Reports First Quarter 2020 Financial Results Exhibit 99.1 CV Sciences, Inc. Reports First Quarter 2020 Financial Results San Diego, CA - May 8, 2020 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2020. First Quarter 2020 and Recent Operating Hi |
|
| May 8, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2020 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sc |
|
| May 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0944 |
|
| April 28, 2020 |
April 28, 2020 VIA EDGAR Mr. Jeffrey Gabor Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: CV Sciences, Inc. Registration Statement on Form S-3 File No. 333-237772 Dear Mr. Gabor: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the un |
|
| April 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| April 21, 2020 |
Exhibit 10.1 NOTE Date 4/15/2020 Note Amount $ 2,906,195.00 Borrower CV Sciences, Inc. Lender JPMorgan Chase Bank, N.A. 1. PROMISE TO PAY. Borrower promises to pay to the order of Lender the Note Amount, plus interest on the unpaid principal balance at the Note Rate, and all other amounts required by this Note. 2. DEFINITIONS. “CARES Act” means the Coronavirus Aid, Relief, and Economic Security Ac |
|
| April 21, 2020 |
CVSI / CV Sciences, Inc. S-3 - - S-3 As filed with the Securities and Exchange Commission on April 21, 2020 Registration No. |
|
| April 21, 2020 |
Form of Specimen Certificate Representing Common Stock. Exhibit 4.1 FORM OF SPECIMEN CERTIFICATE REPRESENTING COMMON STOCK |
|
| April 21, 2020 |
Exhibit 4.3 CV SCIENCES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. Establishm |
|
| March 31, 2020 |
CVSI / CV Sciences, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Definitive Proxy Statement ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p |
|
| March 30, 2020 |
CVSI / CV Sciences, Inc. 10-K - Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ý Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 o Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Science |
|
| March 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| March 20, 2020 |
CVSI / CV Sciences, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Definitive Proxy Statement ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p |
|
| March 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2020 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| March 16, 2020 |
CVSI / CV Sciences, Inc. NT 10-K - - NT 10-K U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR For Period Ended: December 31, 2019 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this Form shall be construed to imply that the Co |
|
| March 16, 2020 |
CV Sciences, Inc. Reports Fiscal Year-End 2019 Financial Results Record full year revenue Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2019 Financial Results Record full year revenue San Diego, CA - March 16, 2020 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2019. Fiscal 2019 |
|
| November 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 8 |
|
| November 8, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission |
|
| November 6, 2019 |
CANV / CannaVest Corp. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 C |
|
| November 5, 2019 |
Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter 2019 Financial Results Increased Retail Distribution by Over 800 Stores San Diego, CA - November 5, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended Sept |
|
| November 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80 |
|
| October 30, 2019 |
CV SCIENCES, INC APPOINTS BETH ALTMAN TO ITS BOARD OF DIRECTORS Exhibit 99.1 CV SCIENCES, INC APPOINTS BETH ALTMAN TO ITS BOARD OF DIRECTORS SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the appointment of Beth Altman to its Board of Directors effective October 24, 2019. “Beth is a highly e |
|
| October 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80 |
|
| October 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 21, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80 |
|
| October 22, 2019 |
CV SCIENCES, INC APPOINTS DR. PAUL BLAKE TO BOARD OF DIRECTORS Exhibit 99.1 CV SCIENCES, INC APPOINTS DR. PAUL BLAKE TO BOARD OF DIRECTORS SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the appointment of Dr. Paul Blake to its Board of Directors effective October 21, 2019. “We are very plea |
|
| September 19, 2019 |
Exhibit 99.1 CV SCIENCES, INC. ANNOUNCES PLANS TO FILE REQUEST FOR CONTINUED EXAMINATION OF ITS US PATENT APPLICATION SAN DIEGO, September 19, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its intention to file for a Request of Continued Examinati |
|
| September 19, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) |
|
| August 27, 2019 |
Exhibit 99.1 CV SCIENCES, INC APPOINTS TERRI FUNK GRAHAM TO BOARD OF DIRECTORS Graham Brings Extensive Fortune 1000 Experience Serving on Boards of Directors and in Senior Leadership Roles SAN DIEGO, August 27, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today |
|
| August 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80- |
|
| August 7, 2019 |
CANV / CannaVest Corp. 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sci |
|
| August 6, 2019 |
Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2019 Financial Results Record quarterly revenue Increased retail distribution by over 1,200 stores San Diego - August 6, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) ("CV Sciences" or the “Company”) announced today its financial results for the quarter ended June 30, 2019. Second Quarter 2019 and Recent Financial and Operating Highlig |
|
| August 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| July 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-094 |
|
| June 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-09 |
|
| June 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-09 |
|
| May 9, 2019 |
CANV / CannaVest Corp. 10-Q Quarterly Report 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ý Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sc |
|
| May 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0944 |
|
| May 8, 2019 |
Exhibit 99.1 CV Sciences, Inc. Reports First Quarter 2019 Financial Results Record quarterly revenue Increased retail distribution by over 1,000 stores Las Vegas, Nevada - May 8, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) ("CV Sciences" or the “Company”) announced today its financial results for the quarter ended March 31, 2019. First Quarter 2019 Financial and Operating Highlights • R |
|
| April 30, 2019 |
CANV / CannaVest Corp. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Definitive Proxy Statement ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p |
|
| April 26, 2019 |
Amended and Restated 2013 Equity Incentive Plan, as amended. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ý Definitive Proxy Statement ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p |
|
| April 15, 2019 |
CANV / CannaVest Corp. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Definitive Proxy Statement ý Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p |
|
| April 15, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| April 15, 2019 |
Letter from Tanner LLC dated April 15, 2019 Exhibit 16.1 April 15, 2019 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: CV Sciences, Inc. Commission File Number 000-54677 Dear Sirs/Madams: We have read Item 4.01 of CV Sciences, Inc.’s Form 8-K dated April 15, 2019, captioned “Changes in Registrant’s Certifying Accountant.” and have the following comments: 1. We have no basis on whi |
|
| April 15, 2019 |
CV Sciences, Inc. Appoints Deloitte & Touche LLP as Auditor Exhibit 99.1 CV Sciences, Inc. Appoints Deloitte & Touche LLP as Auditor LAS VEGAS, April 15, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp CBD products, announced that it has appointed Deloitte & Touche LLP (“Deloitte”) as the Company’s new independent registered public accounting firm. “ |
|
| April 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| March 21, 2019 |
CV SCIENCES, INC. APPOINTS JOERG GRASSER AS NEW CHIEF FINANCIAL OFFICER Exhibit 99.1 CV SCIENCES, INC. APPOINTS JOERG GRASSER AS NEW CHIEF FINANCIAL OFFICER LAS VEGAS, March 21, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp CBD products through its industry-dominating brand, PlusCBD Oil™, announced today the appointment of Joerg Grasser as Chief Financial Offic |
|
| March 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| March 12, 2019 |
CV Sciences, Inc. Reports Fiscal Year-End 2018 Financial Results Record full year revenue Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2018 Financial Results Record full year revenue Las Vegas, Nevada – March 12, 2019 (GLOBE NEWSWIRE) – CV Sciences, Inc. (OTCQB:CVSI) ("CV Sciences" or the “Company”) announced today its financial results for the year ended December 31, 2018. Fiscal 2018 Financial and Operating Highlights • Record revenue of $48.2 million for 2018, an increase |
|
| March 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 12, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| March 12, 2019 |
Employment Agreement, dated December 26, 2018, by and between the Company and Mr. Joerg Grasser. Exhibit 10.32 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of December 26 , 2018 (the “Effective Date”), by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and JOERG GRASSER ("Executive"). Recitals A.The Company operates two distinct business segments: a specialty pharmaceutical division focused on developing and co |
|
| March 12, 2019 |
CANV / CannaVest Corp. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ý Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 o Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Science |
|
| March 12, 2019 |
Exhibit 21.1 List of Subsidiaries 1. Plus CBD, LLC, a Nevada limited liability company. 2. CANNAVEST Acquisition LLC, a Delaware limited liability company. |
|
| January 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 22, 2019 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80 |
|
| January 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 26, 2018 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 8 |
|
| January 8, 2019 |
CV SCIENCES, INC. APPOINTS NEW CHIEF ACCOUNTING OFFICER Exhibit 99.1 CV SCIENCES, INC. APPOINTS NEW CHIEF ACCOUNTING OFFICER January 8, 2019 LAS VEGAS, January 8, 2019 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “we” or “our”), a preeminent supplier and manufacturer of hemp CBD products through its industry-dominating brand PlusCBD Oil™, announced today the appointment of Joerg Grasser as Chief Accounting Officer, effective Decem |
|
| November 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2018 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80 |
|
| November 7, 2018 |
Exhibit 99.1 Record Sales and Gross Profit Lead Strong Quarter for CVSI 10% Sequential Sales Increase Management to Host Third Quarter 2018 Financial Results Conference Call on November 7, 2018 at 4:15pm ET LAS VEGAS, Nov. 07, 2018 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”), announced today its financial results for the third quarter ended Septe |
|
| November 7, 2018 |
CANV / CannaVest Corp. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 C |
|
| August 29, 2018 |
CV Sciences, Inc. Responds to Class Action Lawsuit Exhibit 99.1 CV Sciences, Inc. Responds to Class Action Lawsuit LAS VEGAS, August 28, 2018 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) has been informed of a class action lawsuit filed against the Company that alleges violations of federal securities laws. The Company disputes the allegations in the complaint and will vigorously defend this |
|
| August 29, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2018 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80- |
|
| August 22, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2018 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80- |
|
| August 22, 2018 |
CV SCIENCES, INC. REPAYS remaining debt Exhibit 99.1 CV SCIENCES, INC. REPAYS remaining debt LAS VEGAS, Aug. 22, 2018 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) announced today that it has fully repaid the promissory note payable (“Promissory Note”) to Wiltshire, LLC in cash, thus avoiding any remaining interest payments due on the Note. The Company issued the Promissory Note on |
|
| August 9, 2018 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2018 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| August 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2018 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| August 8, 2018 |
Exhibit 99.1 World-Renowned Neurosurgeon, Health and Nutrition Expert Dr. Joseph Maroon Joins CV Sciences, Inc. Board of Directors Las Vegas, Nevada – August 8, 2018 (GLOBE NEWSWIRE) – CV Sciences, Inc. (OTCQB:CVSI) (the “Company,” “CV Sciences,” “our” or “we”) is pleased to announce the appointment of Joseph Maroon, MD, FACS (“Dr. Maroon”) to its Board of Directors. Dr. Maroon is a clinical profe |
|
| August 7, 2018 |
CBD - BASED PHARMACEUTICAL & CONSUMER PRODUCTS Corporate Presentation – August 4, 2018 Symbol: CVSI EX-99.2 3 cvex9902.htm CORPORATE PRESENTATION Exhibit 99.2 CBD - BASED PHARMACEUTICAL & CONSUMER PRODUCTS Corporate Presentation – August 4, 2018 Symbol: CVSI This presentation may contain certain forward - looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe |
|
| August 7, 2018 |
Exhibit 99.1 Cannabidiol (CBD) Therapeutic Uses for Health and Wellness Joseph C. Maroon, M.D. Board - Certified Neurosurgeon Sports Medicine Consultant Health and Nutrition Expert Aug 4, 2018 1 2 To be Healthy Being physically healthy and fit involves not only how you look, but also how you feel and your overall health. Healthy Factors: 1. Physical 2. Nutritional 3. Toxin Free 4. Spiritual/ Emoti |
|
| August 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2018 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| August 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2018 CV SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-54677 (Commission File Number) 80-0 |
|
| August 2, 2018 |
CV Sciences, Inc. Reports Second Quarter 2018 Financial Results Exhibit 99.1 August 1, 2018 CV Sciences, Inc. Reports Second Quarter 2018 Financial Results · Growth and Profitability Driven by Key Financial Performance Metrics, including Record GAAP Net Income of $3.2 Million · Management to Host Second Quarter 2018 Financial Results Conference Call on August 1, 2018 at 4:15pm ET LAS VEGAS, Aug. 01, 2018 (GLOBE NEWSWIRE) - CV Sciences, Inc. (OTCQB:CVSI) (the “ |
|
| August 1, 2018 |
Employment Agreement, dated June 8, 2018, by and between the Company and Mr. Mona, Jr. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of June 8, 2018 (the “Effective Date”), by and between CV SCIENCES INC., a Delaware corporation (the "Company"), and MICHAEL J. MONA, JR. ("Employee"). Recitals A. The Company operates two distinct business segments: a specialty pharmaceutical division focused on developing and commercializing novel t |
|
| August 1, 2018 |
CANV / CannaVest Corp. FORM 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 ☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54677 CV Sci |
|
| August 1, 2018 |
Exhibit 10.5 DAVID J. VAN HAVERMAAT (Cal. Bar No. 175761) Email: [email protected] JENNIFER T. CALABRESE (Cal. Bar No. 247976) Email: [email protected] Attorneys for Plaintiff Securities and Exchange Commission Michele Wein Layne, Regional Director Alka Patel, Associate Regional Director Amy J. Longo, Regional Trial Counsel 444 South Flower Street, 9th Floor Los Angeles, California 90071 Tele |
|
| August 1, 2018 |
EX-10.6 7 cvscience10q-ex1006.htm CONSENT TO JUDGMENT Exhibit 10.6 DAVID J. VAN HAVERMAAT (Cal. Bar No. 175761) Email: [email protected] JENNIFER T. CALABRESE (Cal. Bar No. 247976) Email: [email protected] Attorneys for Plaintiff Securities and Exchange Commission Michele Wein Layne, Regional Director Alka Patel, Associate Regional Director Amy J. Longo, Regional Trial Counsel 444 South Flowe |
|
| August 1, 2018 |
Exhibit 10.2 CV SCIENCES, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT THIS RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Agreement”), dated as of June 8, 2018 (the “Date of Grant”), is made by and between CV Sciences, Inc., a Delaware corporation (the “Company”), and Michael Mona, Jr. (the “Grantee”). Unless otherwise provided, capitalized terms shall have the meanings given in Section 3. 1. Grant of |
|
| August 1, 2018 |
Employment Agreement, dated June 14, 2018, by and between the Company and Mr. Michael Mona, III. Exhibit 10.4 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into as of June 14, 2018 (the “Effective Date”), by and between CV SCIENCES, INC., a Delaware corporation (the "Company"), and MICHAEL MONA III ("Executive"). Recitals A. The Company and Executive entered into that certain Executive Employment Agreement dated July 6, 2016, and except as ot |
